{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:05:26Z","timestamp":1792004726381,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004943","name":"Department of Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","award":["NCT00593450"],"award-info":[{"award-number":["NCT00593450"]}],"id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010313","name":"Heidelberg Engineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.oret.2018.11.011","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T12:22:51Z","timestamp":1543839771000},"page":"316-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT"],"prefix":"10.1016","volume":"3","author":[{"given":"Cynthia A.","family":"Toth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4434-4046","authenticated-orcid":false,"given":"Vincent","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina P.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezer","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5973-6616","authenticated-orcid":false,"given":"Juan E.","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-shuang","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4872-2902","authenticated-orcid":false,"given":"Sina","family":"Farsiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4249-2467","authenticated-orcid":false,"given":"Maureen G.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2018.11.011_bib1","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","article-title":"Risk of scar in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Daniel","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","article-title":"Macular atrophy in the HARBOR Study for neovascular age-related macular degeneration","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ophtha.2016.10.002","article-title":"Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD trial","volume":"124","author":"Abdelfattah","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 years of Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib6","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","article-title":"Macular morphology and visual acuity in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"120","author":"Jaffe","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ophtha.2018.01.004","article-title":"Development and course of scars in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"125","author":"Daniel","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","article-title":"Macular, morphology and visual acuity in the second year of the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib9","first-page":"CD011346","article-title":"Aflibercept for neovascular age-related macular degeneration","volume":"2","author":"Sarwar","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.oret.2018.11.011_bib10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaophthalmol.2014.1019","article-title":"Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials","volume":"132","author":"Ying","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2018.11.011_bib11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/aos.13522","article-title":"An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration","volume":"95","author":"Berg","year":"2017","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2018.11.011_bib12","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2018.11.011_bib13","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.oret.2017.09.016","article-title":"Linking OCT, angiographic, and photographic lesion components in neovascular age-related macular degeneration","volume":"2","author":"Toth","year":"2018","journal-title":"Ophthalmology Retina"},{"key":"10.1016\/j.oret.2018.11.011_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1167\/iovs.11-7640","article-title":"Validated automatic segmentation of AMD pathology including drusen and geographic atrophy in SD-OCT images","volume":"53","author":"Chiu","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2018.11.011_bib15","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ophtha.2013.07.013","article-title":"Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography","volume":"121","author":"Farsiu","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib16","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.037","article-title":"Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW Trials","volume":"123","author":"Waldstein","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1167\/tvst.6.4.10","article-title":"Algorithms for the automated analysis of age-related macular degeneration biomarkers on optical coherence tomography: a systematic review","volume":"6","author":"Wintergerst","year":"2017","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.oret.2018.11.011_bib18","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1167\/iovs.17-21878","article-title":"Analyzing and predicting visual acuity outcomes of anti-VEGF therapy by a longitudinal mixed effects model of imaging and clinical data","volume":"58","author":"Vogl","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2018.11.011_bib19","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1167\/iovs.16-21053","article-title":"Prediction of Anti-VEGF treatment requirements in neovascular AMD using a machine learning approach","volume":"58","author":"Bogunovic","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2018.11.011_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3928\/23258160-20160229-07","article-title":"Evaluating efficacy of aflibercept in refractory exudative age-related macular degeneration with OCT segmentation volumetric analysis","volume":"47","author":"Choi","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2018.11.011_bib21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD. [published correction appears in Eye (Lond). 2015;29:1397\u20131398]","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2018.11.011_bib22","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1167\/iovs.16-20201","article-title":"Spatial correspondence between intraretinal fluid, subretinal fluid, and pigment epithelial detachment in neovascular age-related macular degeneration","volume":"58","author":"Klimscha","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2018.11.011_bib23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ophtha.2016.12.002","article-title":"Imaging protocols in clinical studies in advanced age-related macular degeneration: recommendations from Classification of Atrophy Consensus Meetings","volume":"124","author":"Holz","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib24","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","article-title":"Subretinal hyperreflective material in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"122","author":"Willoughby","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib25","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib26","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1097\/IAE.0000000000001258","article-title":"Geographic atrophy: semantic considerations and literature review","volume":"36","author":"Schmitz-Valckenberg","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.oret.2018.11.011_bib27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","article-title":"Consensus definition for atrophy associated with age-related macular degeneration on OCT: Classification of Atrophy Report 3","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2018.11.011_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajo.2015.09.032","article-title":"Retinal pigment epithelial atrophy in neovascular age-related macular degeneration after ranibizumab treatment","volume":"161","author":"Kuroda","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2018.11.011_bib29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3928\/23258160-20160229-04","article-title":"Predictors of macular atrophy detected by fundus autofluorescence in patients with neovascular age-related macular degeneration after long-term ranibizumab treatment","volume":"47","author":"Kuehlewein","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2018.11.011_bib30","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1167\/iovs.16-19741","article-title":"OCT angiography-based detection and quantification of the neovascular network in exudative AMD","volume":"57","author":"Lindner","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2018.11.011_bib31","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/IAE.0000000000001576","article-title":"optical coherence tomography angiography reveals blood flow in choroidal neovascular membrane in remission phase of neovascular age-related macular degeneration","volume":"37","author":"Ichiyama","year":"2017","journal-title":"Retina"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653018304603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653018304603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:25:11Z","timestamp":1762853111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653018304603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S2468653018304603"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2018.11.011","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distribution of OCT Features within Areas of Macular Atrophy or Scar after 2 Years of Anti-VEGF Treatment for Neovascular AMD in CATT","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2018.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}